In this article
Abivax
is planning to raise money after releasing key trial data in June, its CEO told CNBC on Tuesday, signaling to potential buyers of the firm that it is in no rush to sell.
Intense takeover rumors have surrounded the French biotech company for months, impacting the volatile stock that rose nearly 1,700% in 2025. Analysts see it as a prime takeover target, and several pharma giants have been rumored as potential buyers.
A second late-stage trial assessing the long-term, maintenance effect of Abivax’ lead, and only, asset obefazimod will read out late in the second quarter. Subject to positive data, it plans to apply for U.S. Food and Drug Administration approval in the fourth quarter, the company has said.
